- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01081834
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
15 lutego 2017 zaktualizowane przez: Janssen Research & Development, LLC
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Szczegółowy opis
Canagliflozin is a drug that is being tested to see if it may be useful in treating patients diagnosed with type 2 diabetes mellitus (T2DM).
This is a randomized (study drug assigned by chance), double blind (neither the patient or the study doctor will know the name of the assigned treatment), parallel-group, 3 arm (patients will be assigned to 1 of 3 treatment groups) multicenter study to determine the efficacy, safety, and tolerability of canagliflozin (100 mg and 300 mg) compared to placebo (a capsule that looks like all the other treatments but has no real medicine) in patients diagnosed with T2DM who are not achieving an adequate response from diet and exercise to control their diabetes.
Approximately 450 patients with inadequate glycemic control with diet and exercise will receive once-daily treatment with canagliflozin 100 mg or 300 mg once daily for 52 weeks or 26 weeks of double-blind treatment with placebo followed by 26 weeks of sitagliptin 100 mg (sitagliptin is an antihyperglycemic agent that will allow patients randomized to the placebo group to improve glycemic control and remain in the study).
Patients will participate in the study for approximately 60 to 68 weeks (referred to as the Main Study).
The study will also include a High Glycemic Substudy in 50 to 100 patients with T2DM who have poorer glycemic control with diet and exercise.
Patients in the substudy will be assigned to receive double-blind canagliflozin 100 mg or 300 mg for 26 weeks and the total duration of patient participatation in the substudy will be approximately 34 to 42 weeks.
During treatment, if a patient's fasting blood sugar remains high despite treatment with study drug and reinforcement with diet and exercise, the patient will receive treatment with metformin (rescue therapy) consistent with local prescribing information.
Study drug will be taken orally (by mouth) once daily before the first meal each day unless otherwise specified.
Patients will take single blind placebo for 1 or 2 weeks (wks) before randomization to the Main Study or the High Glycemic Substudy.
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
678
Faza
- Faza 3
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Halfway, Afryka Południowa
-
Pretoria, Afryka Południowa
-
-
-
-
-
Horn, Austria
-
Salzburg, Austria
-
Wien, Austria
-
-
-
-
-
Pärnu, Estonia
-
Tartu, Estonia
-
Viljandi, Estonia
-
-
-
-
-
Makati, Filipiny
-
Manila, Filipiny
-
Marikina City, Filipiny
-
Pasay, Filipiny
-
-
-
-
-
Guatemala, Gwatemala
-
-
-
-
-
Alcala De Henares, Hiszpania
-
Elche, Hiszpania
-
Girona, Hiszpania
-
Pozuelo De Alarcon, Hiszpania
-
-
-
-
-
Bangalore, Indie
-
Hyderabad, Indie
-
Nagpur, Indie
-
-
-
-
-
Reykjavik, Islandia
-
-
-
-
-
Barranquilla, Kolumbia
-
Bogota, Kolumbia
-
-
-
-
-
Kaunas, Litwa
-
Klaipeda, Litwa
-
Siauliai, Litwa
-
Vilnius, Litwa
-
Vilnius Lt, Litwa
-
-
-
-
-
Kelantan, Malezja
-
Kuala Lumpur, Malezja
-
Kuala Lumpur N/A, Malezja
-
-
-
-
-
Aguascalientes, Meksyk
-
Guadalajara, Meksyk
-
Mex, Meksyk
-
Monterrey, Meksyk
-
Zapopan, Meksyk
-
-
-
-
-
Katowice, Polska
-
Torun, Polska
-
Warszawa, Polska
-
-
-
-
-
Fajardo, Portoryko
-
Ponce, Portoryko
-
San Juan, Portoryko
-
-
-
-
-
Busan, Republika Korei
-
Goyang-Si, Republika Korei
-
Jeonju-Si, Republika Korei
-
Seoul, Republika Korei
-
Wonju-Si, Republika Korei
-
-
-
-
-
Baia Mare, Rumunia
-
Brasov, Rumunia
-
Bucharest, Rumunia
-
Targu Mures, Rumunia
-
-
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone
-
-
California
-
Concord, California, Stany Zjednoczone
-
Greenbrae, California, Stany Zjednoczone
-
Los Angeles, California, Stany Zjednoczone
-
Spring Valley, California, Stany Zjednoczone
-
-
Colorado
-
Colorado Springs, Colorado, Stany Zjednoczone
-
Denver, Colorado, Stany Zjednoczone
-
Northglenn, Colorado, Stany Zjednoczone
-
-
Illinois
-
Springfield, Illinois, Stany Zjednoczone
-
-
Indiana
-
Evansville, Indiana, Stany Zjednoczone
-
-
Louisiana
-
Baton Rouge, Louisiana, Stany Zjednoczone
-
Metairie, Louisiana, Stany Zjednoczone
-
-
New Jersey
-
Meridian, New Jersey, Stany Zjednoczone
-
-
New Mexico
-
Albuquerque, New Mexico, Stany Zjednoczone
-
-
New York
-
New York, New York, Stany Zjednoczone
-
West Seneca, New York, Stany Zjednoczone
-
-
North Carolina
-
Mooresville, North Carolina, Stany Zjednoczone
-
-
Pennsylvania
-
Perryopolis, Pennsylvania, Stany Zjednoczone
-
Pittsburgh, Pennsylvania, Stany Zjednoczone
-
-
South Carolina
-
Taylors, South Carolina, Stany Zjednoczone
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone
-
Houston, Texas, Stany Zjednoczone
-
San Antonio, Texas, Stany Zjednoczone
-
-
Virginia
-
Norfolk, Virginia, Stany Zjednoczone
-
-
-
-
-
Göteborg, Szwecja
-
Lund, Szwecja
-
Malmö, Szwecja
-
Skene, Szwecja
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat do 80 lat (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- All patients must have a diagnosis of T2DM
- Patients in the main study must have a Hemoglobin A1c (HbA1c) between >=7% and <=10% and a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)
- Patients in the High Glycemic Cohort Substudy must have an HbA1c between >10% and <=12% and a FPG <=350 mg/dL (19.44 mmol/L)
Exclusion Criteria:
- History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Canagliflozin 100 mg
Each patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
|
One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
|
Eksperymentalny: Canagliflozin 300 mg
Each patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
|
One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
|
Eksperymentalny: Placebo/Sitagliptin
In the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.
|
One matching placebo capsule orally once daily for 26 weeks (Main Study)
One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change in HbA1c From Baseline to Week 26 (Main Study)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
|
Day 1 (Baseline) and Week 26
|
Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Patients With HbA1c <7% at Week 26 (Main Study)
Ramy czasowe: Week 26
|
The table below shows the percentage of patients with HbA1c <7% at Week 26.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.
|
Week 26
|
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
|
Day 1 (Baseline) and Week 26
|
Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
|
Day 1 (Baseline) and Week 26
|
Percent Change in Body Weight From Baseline to Week 26 (Main Study)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.
|
Day 1 (Baseline) and Week 26
|
Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
|
Day 1 (Baseline) and Week 26
|
Percent Change in Triglycerides From Baseline to Week 26 (Main Study)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.
|
Day 1 (Baseline) and Week 26
|
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (Main Study)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group.
The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.
|
Day 1 (Baseline) and Week 26
|
Percentage of Patients With HbA1c <7% at Week 26 (High Glycemic Substudy)
Ramy czasowe: Week 26
|
The table below shows the percentage of patients with HbA1c <7% at Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Week 26
|
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (High Glycemic Substudy)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (High Glycemic Substudy)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Percent Change in Body Weight From Baseline to Week 26 (High Glycemic Substudy)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (High Glycemic Substudy)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Percent Change in Triglycerides From Baseline to Week 26 (High Glycemic Substudy)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares mean percent change in triglycerides from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy)
Ramy czasowe: Day 1 (Baseline) and Week 26
|
The table below shows the least-squares mean percent change in HDL-C from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy.
|
Day 1 (Baseline) and Week 26
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Publikacje ogólne
- Davies MJ, Merton K, Vijapurkar U, Yee J, Qiu R. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Cardiovasc Diabetol. 2017 Mar 21;16(1):40. doi: 10.1186/s12933-017-0517-7.
- Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017 Feb 27;16(1):29. doi: 10.1186/s12933-017-0511-0.
- Gilbert RE, Mende C, Vijapurkar U, Sha S, Davies MJ, Desai M. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Ther. 2017 Apr;8(2):451-458. doi: 10.1007/s13300-017-0232-0. Epub 2017 Feb 14.
- Qiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017 Mar;33(3):553-562. doi: 10.1080/03007995.2016.1271780. Epub 2017 Jan 4.
- John M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, Canovatchel W, Hamilton G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. Int J Clin Pract. 2016 Sep;70(9):775-85. doi: 10.1111/ijcp.12868.
- Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18.
- Blonde L, Woo V, Mathieu C, Yee J, Vijapurkar U, Canovatchel W, Meininger G. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Curr Med Res Opin. 2015 Nov;31(11):1993-2000. doi: 10.1185/03007995.2015.1082991. Epub 2015 Sep 28.
- Gavin JR 3rd, Davies MJ, Davies M, Vijapurkar U, Alba M, Meininger G. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(9):1693-702. doi: 10.1185/03007995.2015.1067192. Epub 2015 Sep 4.
- Cefalu WT, Stenlof K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015 Jun;58(6):1183-7. doi: 10.1007/s00125-015-3547-2. Epub 2015 Mar 27.
- Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A, Meininger G. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014 Dec;16(12):875-82. doi: 10.1111/jch.12425. Epub 2014 Oct 20.
- Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014 May;126(3):16-34. doi: 10.3810/pgm.2014.05.2753.
- Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014 Sep;30(9):1759-68. doi: 10.1185/03007995.2014.919907. Epub 2014 May 22.
- Sinclair A, Bode B, Harris S, Vijapurkar U, Mayer C, Fung A, Shaw W, Usiskin K, Desai M, Meininger G. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014 Apr 18;14:37. doi: 10.1186/1472-6823-14-37.
- Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21.
- Lavalle-Gonzalez FJ, Eliaschewitz FG, Cerdas S, Chacon Mdel P, Tong C, Alba M. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Curr Med Res Opin. 2016;32(3):427-39. doi: 10.1185/03007995.2015.1121865. Epub 2016 Jan 14.
- Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014 May;57(5):891-901. doi: 10.1007/s00125-014-3196-x. Epub 2014 Mar 1.
- Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014 Feb;30(2):163-75. doi: 10.1185/03007995.2013.850066. Epub 2013 Oct 28.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 marca 2010
Zakończenie podstawowe (Rzeczywisty)
1 sierpnia 2011
Ukończenie studiów (Rzeczywisty)
1 marca 2012
Daty rejestracji na studia
Pierwszy przesłany
4 marca 2010
Pierwszy przesłany, który spełnia kryteria kontroli jakości
4 marca 2010
Pierwszy wysłany (Oszacować)
5 marca 2010
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
23 lutego 2017
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
15 lutego 2017
Ostatnia weryfikacja
1 czerwca 2013
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Zaburzenia metabolizmu glukozy
- Choroby metaboliczne
- Choroby układu hormonalnego
- Cukrzyca
- Cukrzyca typu 2
- Środki hipoglikemizujące
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Inhibitory enzymów
- Hormony
- Hormony, substytuty hormonów i antagoniści hormonów
- Inhibitory proteazy
- Inkretyny
- Inhibitory transportu sodowo-glukozowego 2
- Inhibitory dipeptydylo-peptydazy IV
- Fosforan sitagliptyny
- Kanagliflozyna
Inne numery identyfikacyjne badania
- CR017011
- 28431754DIA3005 (Inny identyfikator: Janssen Research & Development, LLC)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Cukrzyca typu 2
-
Leiden University Medical CenterZakończonyGruczolak przysadki | Guz przysadki | Diabetes Insipidus Cranial Type | Dokrewny; NiedobórHolandia
-
Centre Hospitalier Universitaire de LiegeSanofi; Takeda; University of Liege; Orchard Therapeutics; Centre Hospitalier Régional... i inni współpracownicyRekrutacyjnyWrodzony przerost nadnerczy | Hemofilia A | Hemofilia B | Mukopolisacharydoza I | Mukopolisacharydoza II | Mukowiscydoza | Niedobór alfa 1-antytrypsyny | Anemia sierpowata | Anemia Fanconiego | Przewlekła choroba ziarniniakowa | Choroba Wilsona | Ciężka wrodzona neutropenia | Niedobór transkarbamylazy ornityny | Mukopolisacharydoza... i inne warunkiBelgia
-
UK Kidney AssociationRekrutacyjnyZapalenie naczyń | AL Amyloidoza | Stwardnienie guzowate | Choroba Fabry'ego | Cystynuria | Ogniskowe segmentowe stwardnienie kłębuszków nerkowych | Nefropatia IgA | Syndrom Barttera | Czysta aplazja czerwonokrwinkowa | Nefropatia błoniasta | Atypowy zespół hemolityczno-mocznicowy | Autosomalna dominująca policystyczna... i inne warunkiZjednoczone Królestwo